XML 82 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Account Details - Narrative (Details)
shares in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
position
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
shares
Jan. 31, 2010
agreement
Schedule of Investments        
Number of positions in an unrealized loss position | position 31      
Unrealized losses $ 14,000 $ 162,000    
Investment in Viking common stock 32,200,000 63,100,000    
Gain (loss) from short-term investments 46,365,000 28,540,000 $ (5,263,000)  
Depreciation expense $ 2,900,000 3,800,000 2,400,000  
Finite-lived intangible asset, useful life (in years) 20 years      
Amortization of intangibles $ 33,654,000 34,237,000 34,222,000  
Estimated amortization expense for 2024 32,800,000      
Estimated amortization expense for 2025 32,800,000      
Estimated amortization expense for 2026 32,800,000      
Estimated amortization expense for 2027 32,800,000      
Estimated amortization expense for 2028 32,800,000      
Impairment loss of commercial license rights $ 0 $ 0 $ 0  
Number of CVR agreements | agreement       4
Viking Therapeutics, Inc.        
Schedule of Investments        
Ownership interest (as a percent) 1.70%      
Stock sold of equity method investee (in shares) | shares 5.0   0.6  
Gain (loss) from short-term investments $ 44,400,000   $ 3,600,000  
Minimum        
Schedule of Investments        
Property and equipment, useful life (in years) 1 year      
Maximum        
Schedule of Investments        
Property and equipment, useful life (in years) 9 years